Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 3123

Novelion to Cut Jobs in Restructuring

Following a disappointing 2017 that included an agreement to pay $40 million to resolve criminal charges against its subsidiary Aegerion, Canada-based Novelion Therapeutics will slash an unknown number of jobs as it initiates “significant cost reduction plans.”

Read More »

Sanofi to Eliminate 400 U.S. Jobs

Paris, France-based Sanofi announced major restructuring involving layoffs. About 400 jobs cut will be in the U.S.

Read More »

Teva’s Job Cuts Hit 208 Philadelphia Employees

Cuts implemented by Israel-based Teva Pharmaceutical hit the shores of the United States. The company is laying off 208 people in the Philadelphia area.

Read More »

Ironshore Laid Off Staff, Quietly Closed Down

Almost one year after filing a New Drug Application for an ADHD drug and less than one year after announcing it secured $200 million in financing, Ironshore Pharmaceuticals closed its doors.

Read More »

OvaScience Pinks Slips Nearly 50 Percent of Workforce

OvaScience is restructuring to cut costs. As part of that process, the company is laying off about half of its staff.

Read More »

265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.

Read More »

Israel’s Protalix to Slash 20 Percent of Workforce

Share prices for Protalix Biotherapeutics were up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease. Despite that positive news on its pipeline, Protalix is reportedly set to terminate 50 employees, which amounts to about 20 percent of its workforce.

Read More »

Teva Announces New Organization Structure

Teva Pharmaceutical Industries announced a new organization and leadership structure aimed to achieve better commercial focus and drive value creation.

Read More »

Ardelyx to Ditch Phase III Hyperkalemia Drug

Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.

Read More »

Life Science Giant PPD Cuts an Undisclosed Number of Jobs

CRO giant Pharmaceutical Product Development LLC terminated a number of employees in its human resources department, but has provided few details about the job cuts, according to reports.

Read More »

X-Spine Systems to Shut Down, Lays Off 54 Employees

X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.

Read More »

Merck to Cut 1,800 Jobs and Add 960 in Chronic Care

As part of a new sales team structure, Merck plans to cut 1,800 sales jobs. At the same time, the company expects to add 960 jobs to a new sales force focused on chronic care.

Read More »

450 Jobs Eliminated as Novartis Shuts Down Colorado Facility

Switzerland-based Novartis is closing the company’s generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.

Read More »

Massachusetts’ Biostage Slashes 71 Percent of Staff, Evaluating Strategic Alternatives

An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage Inc. To maintain operations, the company is terminating 17 employees, about 71 percent of its workforce.

Read More »

Ardelyx Shares Soared After Positive Phase III Results for Tenapanor

Two months after slashing 28 percent of its workforce as part of a strategic review, Ardelyx Inc. announced positive Phase III results for tenapanor, its irritable bowel syndrome with constipation (IBS-C).

Read More »

Trevena Slashes 30 Percent of R&D Jobs Amid Cost Cuts

Trevena Inc. is banking its future on possible approval of troubled pain medication Olinvo eight months after Phase III data raised some questions over the drug’s safety profile.

Read More »

Lilly’s lung cancer drug fails key study goal

Eli Lilly’s drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial.

Read More »

Boston’s Juniper Pharma Suspends Program, Cuts 8% of R&D Jobs and CMO Steps Down

Juniper Pharmaceuticals, after a strategic evaluation, decided to prioritize its resources on the company’s core businesses of Crinone progesterone gel and Juniper Pharma Services. As a result of the changes, Juniper plans to lay off 8 percent of its staff, mostly in the new product research-and-development areas.

Read More »

Alexion Wants Fresh Start, Slashes 20% of Jobs and Will Move HQ to Boston

Alexion Pharmaceuticals announced plans to cut costs by closing several sites, moving its headquarters and laying off 20 percent of staff. The job cuts follow 210 layoffs in March 2017.

Read More »

SoCal’s Cytori Pink Slips 50 Percent of Workforce in Restructuring

Cytori Therapeutics is terminating half of its employees a little more than one month after the company’s late-stage cell therapy to treat scleroderma failed to achieve statistical significance for both the primary and secondary trial endpoints.

Read More »

Page 1 of 3123

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation